miltefosine has been researched along with Emesis in 6 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Excerpt | Relevance | Reference |
---|---|---|
"The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with oral miltefosine at a dose of 50 mg thrice daily in patients with metastatic soft tissue sarcomas." | 9.07 | Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study. ( Kok, T; Krzemieniecki, K; Mouridsen, H; Poveda, A; van Glabbeke, M; van Pottelsberghe, C; Verweij, J, 1993) |
"34 patients with metastatic colorectal cancer were treated with the ether lipid miltefosine (hexadecylphosphocholine)." | 9.07 | Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. ( Planting, AS; Stoter, G; Verweij, J, 1993) |
"The EORTC Soft Tissue and Bone Sarcoma Group conducted a phase II study with oral miltefosine at a dose of 50 mg thrice daily in patients with metastatic soft tissue sarcomas." | 5.07 | Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study. ( Kok, T; Krzemieniecki, K; Mouridsen, H; Poveda, A; van Glabbeke, M; van Pottelsberghe, C; Verweij, J, 1993) |
"34 patients with metastatic colorectal cancer were treated with the ether lipid miltefosine (hexadecylphosphocholine)." | 5.07 | Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer. ( Planting, AS; Stoter, G; Verweij, J, 1993) |
"Miltefosine is an oral medication with anti-leishmania activity and may increase the cure rates and improve compliance." | 2.75 | Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial. ( Ampuero, J; Carvalho, EM; Guimarães, LH; Machado, PR; Penna, G; Rocha, AT; Schriefer, A; Sousa, RS; Talhari, A; Villasboas, L, 2010) |
"Treatment with miltefosine at 100-150 mg/day for 4 weeks has promise as an effective oral treatment of visceral leishmaniasis including antimony-resistant infection." | 2.69 | Trial of oral miltefosine for visceral leishmaniasis. ( Goyal, AK; Hilgard, P; Makharia, MK; Mandal, AK; Murray, HW; Rosenkaimer, F; Sundar, S; Voss, A, 1998) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (66.67) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Machado, PR | 1 |
Ampuero, J | 1 |
Guimarães, LH | 1 |
Villasboas, L | 1 |
Rocha, AT | 1 |
Schriefer, A | 1 |
Sousa, RS | 1 |
Talhari, A | 1 |
Penna, G | 1 |
Carvalho, EM | 1 |
Stekar, J | 1 |
Hilgard, P | 2 |
Voegeli, R | 1 |
Maurer, HR | 1 |
Engel, J | 1 |
Kutscher, B | 1 |
Nössner, G | 1 |
Schumacher, W | 1 |
Verweij, J | 2 |
Krzemieniecki, K | 1 |
Kok, T | 1 |
Poveda, A | 1 |
van Pottelsberghe, C | 1 |
van Glabbeke, M | 1 |
Mouridsen, H | 1 |
Planting, AS | 1 |
Stoter, G | 1 |
Sundar, S | 2 |
Rosenkaimer, F | 1 |
Makharia, MK | 1 |
Goyal, AK | 1 |
Mandal, AK | 1 |
Voss, A | 2 |
Murray, HW | 2 |
Makharia, A | 1 |
More, DK | 1 |
Agrawal, G | 1 |
Fischer, C | 1 |
Bachmann, P | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Clinical Trial to Assess Efficacy and Safety of Orally Administered Miltefosine in Brazilian Patients With Cutaneous Leishmaniasis Compared to the Standard Care as Active Control[NCT00600548] | Phase 2 | 180 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
Intervention | participants (Number) |
---|---|
Miltefosine | 85 |
Glucantime® | 103 |
Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
Intervention | participants (Number) |
---|---|
Miltefosine | 34 |
Glucantime® | 14 |
Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
Intervention | Participants (Number) |
---|---|
Miltefosine | 3 |
Glucantime® | 4 |
Thermotherapy | 6 |
5 trials available for miltefosine and Emesis
Article | Year |
---|---|
Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial.
Topics: Abdominal Pain; Administration, Oral; Adolescent; Adult; Aged; Antimony; Antiprotozoal Agents; Brazi | 2010 |
Phase II study of miltefosine (hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult--an EORTC Soft Tissue and Bone Sarcoma Group Study.
Topics: Administration, Oral; Adolescent; Adult; Female; Humans; Male; Middle Aged; Nausea; Phosphorylcholin | 1993 |
Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; Female; Humans; Leuk | 1993 |
Trial of oral miltefosine for visceral leishmaniasis.
Topics: Administration, Oral; Adolescent; Adult; Antiprotozoal Agents; Drug Administration Schedule; Humans; | 1998 |
Short-course of oral miltefosine for treatment of visceral leishmaniasis.
Topics: Administration, Oral; Adult; Antiprotozoal Agents; Diarrhea; Drug Administration Schedule; Female; H | 2000 |
1 other study available for miltefosine and Emesis
Article | Year |
---|---|
Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Antineoplastic Agents; Cell Differentiation; Female; Ferr | 1993 |